Aurora Cannabis Stock: What’s Behind Its Astonishing 135% Rally?

Aurora Cannabis stock has crushed market returns since its impressive Q3 results. Is this rally sustainable?

| More on:
Question marks in a pile

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Shares of marijuana giant Aurora Cannabis (TSX:ACB)(NYSE:ACB) gained momentum in the last three trading sessions. Aurora stock rose by a staggering 67% on May 15 after it rose by 11% a day earlier. Aurora stock price gained over 20% in pre-market trading on the New York Stock Exchange yesterday, bringing total returns of the stock to a staggering 135% in the last three trading days.

Investors were buoyed after the pot stock announced its fiscal third quarter of 2020 results. Aurora Cannabis reported net revenue of $75.5 million in Q3, up from $56.03 million in Q2.

Its cannabis net revenue was $69.64 million, up from $52.7 million in the same period. This strong performance was driven by a 24% increase in recreational cannabis and a 13.5% rise in medical cannabis.

Aurora Cannabis also managed to improve its cash position to $230.2 million. It used $154.6 million in cash in the March quarter, a sequential decline of 43%. Aurora Cannabis sold 12,729 kilograms of marijuana in Q3, up from 9,501 kilograms in Q2.

Aurora stock price was sent higher after the company’s management stated that it would report a positive EBITDA in the first quarter of fiscal 2021. It intends to reduce losses by focusing on cost initiatives, improving gross margins, and lower selling, general and administrative expenses.

ACB’s leadership team maintained that it’s difficult to predict near-term revenue due to COVID-19 related issues. However, its huge market presence and focus on cost efficiencies will help improve EBITDA in the upcoming quarters.

Aurora Cannabis stock upgraded by investment banks

Aurora Cannabis’ robust Q3 performance resulted in stock upgrades. Investment bank Piper Sandler upgraded ACB stock from underweight to neutral with a price target from US$10. This investment bank is optimistic about the company’s expanding margin and resumption of sales in Europe.

ACB Chart

ACB data by YCharts

MKM Partners maintained a neutral rating. However, it increased Aurora’s stock price target from $1 to $12. Aurora stock is listed on the TSX and closed trading at a price of $15.35 last week. Despite, the recent optimism, Aurora Cannabis isn’t out of the woods yet. We can see the volatility in the above Aurora stock chart, which could continue in the short term.

The cannabis heavyweight acquired several companies over the last few years. Due to the ongoing bullish sentiment in the cannabis space prevalent at that time, Aurora paid a premium to acquire these companies. This premium is known as goodwill and is the difference between the book value and the company’s acquisition price.

In the December quarter, Aurora Cannabis reported a goodwill impairment write-down of $762.2 million. This impairment charge could rise to a billion in the next few quarters as Aurora’s goodwill stands at $2.41 billion, accounting for 51.2% of total assets.

Aurora Cannabis is also grappling with structural issues like a thriving black market and slow rollout of retail stores in Canada. This has driven inventory levels higher to $251.2 million in Q3, up from $113.6 million at the end of fiscal 2019.

While investors have seen a massive bump in Aurora stock price recently, it’s still trading 91% below record highs.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »